Inventiva announces the nomination of Andre Turenne as Director
Daix (France), Long Island City (New
York, United States), March 28, 2024 – Inventiva (Euronext
Paris and Nasdaq: IVA) (the “Company”), a clinical-stage
biopharmaceutical company focused on the development of oral small
molecule therapies for the treatment of metabolic
dysfunction-associated steatohepatitis (“MASH”), also known as
non-alcoholic steatohepatitis (“NASH”) and other diseases with
significant unmet medical needs, today announced the nomination of
Andre Turenne to its Board of Directors. Mr. Turenne’s appointment
will be submitted to the shareholders for ratification at the next
general shareholder meeting.
Frédéric Cren, Chairman, Chief Executive
Officer, and cofounder of Inventiva: “We are extremely
pleased that our Board of Directors has proposed the appointment of
Andre. His deep knowledge of the industry and his experience in
deploying strategic collaborations and executing M&A
transactions will be a strategic experience and know-how for
Inventiva, as we enter the final stretch of our Phase III clinical
trial of lanifibranor in NASH. We look forward to welcoming Andre
as the newest member of our Board of Directors.”
Mr. Turenne has more than 20 years of global
experience in the pharmaceutical industry. He is currently
President and Chief Executive Officer of the Boston-based biotech
Matchpoint Therapeutics, and Advisor to Atlas Venture since 2021.
Prior to joining Matchpoint, Mr. Turenne served as President and
Chief Executive Officer of Voyager Therapeutics. He previously held
senior leadership positions at Sanofi, including Senior Vice
President and Global Head of Business Development & Licensing,
responsible for strategic transactions across therapeutic areas,
modalities, and geographies. Mr. Turenne holds a B.A. from
Kalamazoo College and an M.B.A. from the Tuck School of Business at
Dartmouth.
Andre Turenne,
non-executive director nominee: “I am delighted to
have the opportunity to join the Board of Directors of Inventiva,
which is at a pivotal stage in its clinical program in NASH. I am
eager to collaborate with the board and leadership team to support
the company towards fulfilling its mission.”
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH/NASH,
and other diseases with significant unmet medical need. The Company
benefits from a strong expertise and experience in the domain of
compounds targeting nuclear receptors, transcription factors and
epigenetic modulation. Inventiva is currently advancing one
clinical candidate, has a pipeline of two preclinical programs and
continues to explore other development opportunities to add to its
pipeline.
Inventiva’s lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial,
NATiV3, for the treatment of adult patients with MASH/NASH, a
common and progressive chronic liver disease for which there are
currently no approved therapies.
Inventiva’s pipeline also includes odiparcil, a
drug candidate for the treatment of adult MPS VI patients. As part
of Inventiva’s decision to focus clinical efforts on the
development of lanifibranor, it suspended its clinical efforts
relating to odiparcil and is reviewing available options with
respect to its potential further development. Inventiva is also in
the process of selecting a candidate for its Hippo signaling
pathway program.
The Company has a scientific team of
approximately 90 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive
library of approximately 240,000 pharmacologically relevant
molecules, approximately 60% of which are proprietary, as well as a
wholly-owned research and development facility.
Inventiva is a public company listed on
compartment B of the regulated market of Euronext Paris (ticker:
IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
Inventiva Pascaline ClercEVP, Strategy and
Corporate Affairsmedia@inventivapharma.com +1 202
499 8937 |
Brunswick GroupTristan Roquet Montegon /Aude
Lepreux /Julia CailleteauMedia
relationsinventiva@brunswickgroup.com +33 1 53 96 83
83 |
Westwicke, an ICR CompanyPatricia L. BankInvestor
relationspatti.bank@westwicke.com
+1 415 513-1284 |
|
|
|
|
|
|
Important Notice
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release are forward-looking statements.
These statements include, but are not limited
to, forecasts and estimates with respect to the results of
Inventiva’s annual general meeting of shareholders, including with
respect to the appointment of Mr. Turenne, Inventiva’s clinical
trials, including the ongoing NATiV3 Phase III clinical trial with
lanifibranor in MASH/NASH, its pipeline and preclinical and
clinical development plans, the potential development of and
regulatory pathway for odiparcil, and future activities,
expectations, plans, growth and prospects of Inventiva. Certain of
these statements, forecasts and estimates can be recognized by the
use of words such as, without limitation, “believes”,
“anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”,
“may”, “will”, “would”, “could”, “might”, “should”, “designed”,
“hopefully”, “target”, “potential”, “opportunity”, “possible”,
“aim”, and “continue” and similar expressions. Such statements are
not historical facts but rather are statements of future
expectations and other forward-looking statements that are based on
management's beliefs. These statements reflect such views and
assumptions prevailing as of the date of the statements and involve
known and unknown risks and uncertainties that could cause future
results, performance, or future events to differ materially from
those expressed or implied in such statements. Actual events are
difficult to predict and may depend upon factors that are beyond
Inventiva's control. There can be no guarantees with respect to
pipeline product candidates that the clinical trial results will be
available on their anticipated timeline, that future clinical
trials will be initiated as anticipated, that product candidates
will receive the necessary regulatory approvals, or that any of the
anticipated milestones by Inventiva or its partners will be reached
on their expected timeline, or at all. Future results may turn out
to be materially different from the anticipated future results,
performance or achievements expressed or implied by such
statements, forecasts and estimates, due to a number of factors,
including that Inventiva cannot provide assurance on the impacts of
the SUSAR on enrolment or the ultimate impact on the results or
timing of the NATiV3 trial or regulatory matters with respect
thereto, that Inventiva is a clinical-stage company with no
approved products and no historical product revenues, Inventiva has
incurred significant losses since inception, Inventiva has a
limited operating history and has never generated any revenue from
product sales, Inventiva will require additional capital to finance
its operations, in the absence of which, Inventiva may be required
to significantly curtail, delay or discontinue one or more of its
research or development programs or be unable to expand its
operations or otherwise capitalize on its business opportunities
and may be unable to continue as a going concern, Inventiva's
future success is dependent on the successful clinical development,
regulatory approval and subsequent commercialization of current and
any future product candidates, preclinical studies or earlier
clinical trials are not necessarily predictive of future results
and the results of Inventiva's and its partners’ clinical trials
may not support Inventiva's and its partners’ product candidate
claims, Inventiva's expectations with respect to its clinical
trials may prove to be wrong and regulatory authorities may require
holds and/or amendments to Inventiva’s clinical trials, Inventiva’s
expectations with respect to the clinical development plan for
lanifibranor for the treatment of MASH/NASH may not be realized and
may not support the approval of a New Drug Application, Inventiva
and its partners may encounter substantial delays beyond
expectations in their clinical trials or fail to demonstrate safety
and efficacy to the satisfaction of applicable regulatory
authorities, the ability of Inventiva and its partners to recruit
and retain patients in clinical studies, enrollment and retention
of patients in clinical trials is an expensive and time-consuming
process and could be made more difficult or rendered impossible by
multiple factors outside Inventiva's and its partners’ control,
Inventiva's product candidates may cause adverse drug reactions or
have other properties that could delay or prevent their regulatory
approval, or limit their commercial potential, Inventiva faces
substantial competition and Inventiva’s and its partners' business,
and preclinical studies and clinical development programs and
timelines, its financial condition and results of operations could
be materially and adversely affected by geopolitical events, such
as the conflict between Russia and Ukraine and related sanctions,
impacts and potential impacts on the initiation, enrollment and
completion of Inventiva’s and its partners’ clinical trials on
anticipated timelines and the state of war between Israel and Hamas
and the related risk of a larger conflict, health epidemics, and
macroeconomic conditions, including global inflation, rising
interest rates, uncertain financial markets and disruptions in
banking systems, and the vote of Inventiva’s shareholders. Given
these risks and uncertainties, no representations are made as to
the accuracy or fairness of such forward-looking statements,
forecasts, and estimates. Furthermore, forward-looking statements,
forecasts and estimates only speak as of the date of this press
release. Readers are cautioned not to place undue reliance on any
of these forward-looking statements.
Please refer to the Universal Registration
Document for the year ended December 31, 2022 filed with the
Autorité des Marchés Financiers on March 30, 2023 as amended on
August 31, 2023, the Annual Report on Form 20-F for the year ended
December 31, 2022 filed with the Securities and Exchange Commission
(the “SEC”) on March 30, 2023, and the Half-Year Report for the six
months ended June 30, 2023 on Form 6-K filed with the SEC on
October 3, 2023, for other risks and uncertainties affecting
Inventiva, including those described under the caption “Risk
Factors”, and in our future filings with the SEC, including our
Annual Report on Form 20-F for the year ended December 31, 2023 to
be filed with the SEC. Other risks and uncertainties of which
Inventiva is not currently aware may also affect its
forward-looking statements and may cause actual results and the
timing of events to differ materially from those anticipated. All
information in this press release is as of the date of the release.
Except as required by law, Inventiva has no intention and is under
no obligation to update or review the forward-looking statements
referred to above. Consequently, Inventiva accepts no liability for
any consequences arising from the use of any of the above
statements.
- Inventiva - PR - Nomination New Board Member - EN - 03 28
2024
Inventiva (TG:6IV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inventiva (TG:6IV)
Historical Stock Chart
From Sep 2023 to Sep 2024